Two peer-reviewed studies examining vaccine safety across nearly 12 million Americans were completed, accepted by medical journals, and then withdrawn at the direction of FDA political appointees who refused to sign off on their publication. The research had already passed independent peer review and been accepted for publication in Drug Safety and Vaccine journals.
The first study tracked 7.5 million Medicare beneficiaries for 14 specific adverse outcomes following 2023-2024 Covid-19 vaccination over a 90-day period. It found only one safety signal that exceeded statistical noise: anaphylaxis occurring at roughly one case per million Pfizer-BioNTech doses. A second study examined 4.2 million recipients ages six months to 64 years and identified only rare febrile-seizure and myocarditis signals already documented on vaccine labels. A third analysis of the Shingrix vaccine confirmed an elevated but still-low Guillain-Barré risk long listed on the package insert.
In October, FDA scientists were directed to withdraw the Covid studies. In February, top officials blocked submission of Shingrix safety abstracts to a major drug-safety conference. The agency's stated objection, that authors "drew broad conclusions that were not supported by the underlying data," represents standard peer review work. Journals routinely ask authors to narrow language and revise discussion sections. Political appointees instructing staff scientists to withdraw already-accepted manuscripts is procedurally without precedent.
The timing raises additional concerns. In late November, an FDA memo linking 10 children's deaths to Covid-19 vaccination received agency release and broad media coverage, despite remaining unsubstantiated. Two studies showing serious adverse effects to be extremely rare across millions of doses remain unpublished. This asymmetry suggests vaccine-skeptical claims move through the agency with low evidentiary standards while reassuring safety data faces barriers no peer-reviewed paper could realistically overcome.
The suppression extends beyond Covid vaccines. The CDC has shed roughly a quarter of its workforce over the past year and operates under directives that include editing its weekly scientific journal. Both agencies sit within the same Health and Human Services department now directing FDA scientists to block vaccine-safety research already vetted by independent peer review.
The practical stakes grow urgent. The FIFA World Cup opens in the United States on June 11, drawing 48 teams and over 6 million attendees across 39 days at 11 host cities. The tournament arrives as Mexico reports more than 9,000 measles cases since February 2025, Canada has lost measles elimination status as of November, and U.S. vaccination coverage sits below the 95% threshold needed for population immunity. Heightened surveillance transparency would be standard protocol.
Instead, three independent channels that once alerted physicians to emerging health threats have been paused, edited, or captured. For clinicians managing respiratory clusters or unusual presentations during or after the tournament, the question becomes whether the federal surveillance system will still report what it detects. That question echoes one asked in June 1981 when a brief MMWR report described five cases of Pneumocystis pneumonia in Los Angeles. The virtue of that system then was not that it understood what was unfolding. It was that it remained free to publish what it saw.
Author James Rodriguez: "When the medical system itself cannot trust the information flowing from its regulatory agencies, patient safety depends on individual clinician judgment operating in the dark."
Comments